PRAME and cancer: In contrast, cancer cells that did not present PRAME-pHLA complexes on their cell surfaces (HLA-A*02:01– NSCLC cells: NCI-H1693 and PRAME– ovarian TYK-nu used as controls for these experiments) did not elicit T cell redirection and activation or cytotoxicity.